Dimensional Fund Advisors LP Boosts Stake in Privia Health Group, Inc. (NASDAQ:PRVA)

Dimensional Fund Advisors LP grew its holdings in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,416,235 shares of the company's stock after acquiring an additional 138,747 shares during the period. Dimensional Fund Advisors LP owned about 1.18% of Privia Health Group worth $27,687,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Riverbridge Partners LLC increased its stake in Privia Health Group by 19.7% during the fourth quarter. Riverbridge Partners LLC now owns 5,824,458 shares of the company's stock worth $113,868,000 after acquiring an additional 958,418 shares during the last quarter. Loomis Sayles & Co. L P increased its stake in Privia Health Group by 55.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,418,234 shares of the company's stock worth $27,727,000 after acquiring an additional 503,002 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Privia Health Group by 111.7% during the fourth quarter. JPMorgan Chase & Co. now owns 398,738 shares of the company's stock worth $7,795,000 after acquiring an additional 210,354 shares during the last quarter. Marshall Wace LLP increased its stake in Privia Health Group by 111.8% during the fourth quarter. Marshall Wace LLP now owns 338,259 shares of the company's stock worth $6,613,000 after acquiring an additional 178,548 shares during the last quarter. Finally, Barclays PLC increased its stake in Privia Health Group by 240.3% during the third quarter. Barclays PLC now owns 224,018 shares of the company's stock worth $4,079,000 after acquiring an additional 158,188 shares during the last quarter. 94.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PRVA. Robert W. Baird upped their target price on Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a research note on Tuesday, April 15th. Truist Financial upped their target price on Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $30.00 target price on shares of Privia Health Group in a research note on Thursday, April 10th. JMP Securities reaffirmed a "market outperform" rating and set a $29.00 target price on shares of Privia Health Group in a research note on Monday, April 28th. Finally, Canaccord Genuity Group upped their target price on Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $27.38.

Privia Health Group Trading Down 0.2%

Privia Health Group stock traded down $0.05 during trading on Friday, hitting $25.02. The company had a trading volume of 1,314,984 shares, compared to its average volume of 766,349. Privia Health Group, Inc. has a 1-year low of $15.92 and a 1-year high of $26.09. The company's 50 day simple moving average is $23.38 and its 200-day simple moving average is $22.34. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of 250.23, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87.

Insiders Place Their Bets

In other Privia Health Group news, CEO Parth Mehrotra sold 15,100 shares of the firm's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $352,283.00. Following the transaction, the chief executive officer now owns 454,281 shares of the company's stock, valued at approximately $10,598,375.73. This trade represents a 3.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO David Mountcastle sold 5,630 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the sale, the chief financial officer now owns 179,676 shares of the company's stock, valued at $4,021,148.88. This trade represents a 3.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,484 shares of company stock worth $799,163 over the last 90 days. Corporate insiders own 10.70% of the company's stock.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.